These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20129532)

  • 1. Myocardial infarct size reduction with pexelizumab: the role of chance is patently clear.
    Gibson CM; Pride YB
    JACC Cardiovasc Imaging; 2010 Jan; 3(1):61-3. PubMed ID: 20129532
    [No Abstract]   [Full Text] [Related]  

  • 2. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial.
    Patel MR; Worthley SG; Stebbins A; Dill T; Rademakers FE; Valeti US; Barsness GW; Van de Werf F; Hamm CW; Armstrong PW; Granger CB; Kim RJ
    JACC Cardiovasc Imaging; 2010 Jan; 3(1):52-60. PubMed ID: 20129531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.
    Wöhrle J; Merkle N; Kunze M; Cristea E; Mehran R; Rottbauer W; Stone GW
    Catheter Cardiovasc Interv; 2012 Jun; 79(7):1083-9. PubMed ID: 22162175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrocardiographic measures of myocardial function and necrosis.
    Wagner GS; Hakacova N
    JACC Cardiovasc Imaging; 2009 Oct; 2(10):1195-7. PubMed ID: 19833309
    [No Abstract]   [Full Text] [Related]  

  • 5. Aborted myocardial infarction after primary percutaneous coronary intervention: magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
    Patel MR; Westerhout CM; Granger CB; Brener SJ; Fu Y; Siha H; Kim RJ; Armstrong PW
    Am Heart J; 2013 Feb; 165(2):226-33. PubMed ID: 23351826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy.
    Ezekowitz JA; Armstrong PW; Granger CB; Theroux P; Stebbins A; Kim RJ; Patel MR
    Am Heart J; 2010 Aug; 160(2):272-8. PubMed ID: 20691832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Chia S; Senatore F; Raffel OC; Lee H; Wackers FJ; Jang IK
    JACC Cardiovasc Interv; 2008 Aug; 1(4):415-23. PubMed ID: 19463339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extent of RV dysfunction and myocardial infarction assessed by CMR are independent outcome predictors early after STEMI treated with primary angioplasty.
    Miszalski-Jamka T; Klimeczek P; Tomala M; Krupiński M; Zawadowski G; Noelting J; Lada M; Sip K; Banyś R; Mazur W; Kereiakes DJ; Zmudka K; Pasowicz M
    JACC Cardiovasc Imaging; 2010 Dec; 3(12):1237-46. PubMed ID: 21163452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visualizing myocardial salvage: new methods, new insights.
    Reichek N; Kodali V
    JACC Cardiovasc Imaging; 2010 May; 3(5):501-3. PubMed ID: 20466345
    [No Abstract]   [Full Text] [Related]  

  • 10. Early electrocardiographic findings and MR imaging-verified microvascular injury and myocardial infarct size.
    Nijveldt R; van der Vleuten PA; Hirsch A; Beek AM; Tio RA; Tijssen JG; Piek JJ; van Rossum AC; Zijlstra F
    JACC Cardiovasc Imaging; 2009 Oct; 2(10):1187-94. PubMed ID: 19833308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of myocardial salvage during acute myocardial infarction: evaluation with a combined angiographic and CMR myocardial salvage index.
    Ortiz-Pérez JT; Lee DC; Meyers SN; Davidson CJ; Bonow RO; Wu E
    JACC Cardiovasc Imaging; 2010 May; 3(5):491-500. PubMed ID: 20466344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation on a theme: CMR as the "one-stop shop" for risk stratification after infarction?
    Wu KC
    JACC Cardiovasc Imaging; 2009 Jul; 2(7):843-5. PubMed ID: 19608134
    [No Abstract]   [Full Text] [Related]  

  • 13. Value of a new multiparametric score for prediction of microvascular obstruction lesions in ST-segment elevation myocardial infarction revascularized by percutaneous coronary intervention.
    Amabile N; Jacquier A; Gaudart J; Sarran A; Shuaib A; Panuel M; Moulin G; Bartoli JM; Paganelli F
    Arch Cardiovasc Dis; 2010 Oct; 103(10):512-21. PubMed ID: 21130964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rediscovery of infarct imaging by cardiac CT.
    de Feyter PJ; Nieman K
    JACC Cardiovasc Imaging; 2009 Sep; 2(9):1082-4. PubMed ID: 19761986
    [No Abstract]   [Full Text] [Related]  

  • 15. A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial.
    Stebbins A; Mehta RH; Armstrong PW; Lee KL; Hamm C; Van de Werf F; James S; Toftegaard-Nielsen T; Seabra-Gomes R; White HD; Granger CB;
    Circ Cardiovasc Interv; 2010 Oct; 3(5):414-22. PubMed ID: 20858863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Welsh RC; Granger CB; Westerhout CM; Blankenship JC; Holmes DR; O'Neill WW; Hamm CW; Van de Werf F; Armstrong PW;
    JACC Cardiovasc Interv; 2010 Mar; 3(3):343-51. PubMed ID: 20298996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
    Granger CB; Mahaffey KW; Weaver WD; Theroux P; Hochman JS; Filloon TG; Rollins S; Todaro TG; Nicolau JC; Ruzyllo W; Armstrong PW;
    Circulation; 2003 Sep; 108(10):1184-90. PubMed ID: 12925454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Still searching for a new therapeutic strategy for acute myocardial infarction.
    Saito Y
    Circ J; 2010 Nov; 74(11):2290-2. PubMed ID: 20962420
    [No Abstract]   [Full Text] [Related]  

  • 19. Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction.
    Rasoul S; Ottervanger JP; de Boer MJ; Dambrink JH; Hoorntje JC; Marcel Gosselink AT; Zijlstra F; Suryapranata H; van 't Hof AW;
    Coron Artery Dis; 2009 Sep; 20(6):415-21. PubMed ID: 19641460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program.
    Hassan AK; Liem SS; van der Kley F; Bergheanu SC; Wolterbeek R; Bosch J; Bootsma M; Zeppenfeld K; van der Laarse A; Atsma DE; Jukema JW; Schalij MJ
    Catheter Cardiovasc Interv; 2009 Aug; 74(2):335-43. PubMed ID: 19642182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.